Target intelligence / Profile preview

Protein tyrosine phosphatase non-receptor type 23 (PTPN23)

Target
PTPN23
Molecular classification
Enzyme, Protein tyrosine phosphatase (non-receptor type)
01

Overview

Protein tyrosine phosphatase non-receptor type 23 (PTPN23) is a cytosolic enzyme belonging to the PTP superfamily, which regulates the phosphorylation state of proteins on tyrosine residues. PTPN23 plays key roles in endosomal sorting via the ESCRT complex, acts as a tumor suppressor, and is involved in pre-mRNA splicing, ciliogenesis, and maintenance of cardiac T-tubule organization. It interacts with sarcomeric and membrane-associated proteins (e.g., α-actinin, dystrophin-glycoprotein complex) and participates in cytoskeletal anchoring in cardiomyocytes. Dysregulation of PTPN23 has been linked to neurodevelopmental disorders, structural brain anomalies, various cancers, and cardiac dysfunction. As with other protein tyrosine phosphatases, targeting PTPN23 for therapeutic modulation poses significant challenges due to the highly conserved nature of PTP active sites and potential for widespread effects on cellular signaling networks[1][2][4][5].

Other names
HD-PTPKIAA1471PTP-TD14DKFZP564F0923His domain-containing protein tyrosine phosphataseProtein tyrosine phosphatase TD14HDPTPNEDBASS
02

Mechanism of action

Inhibitors would block its phosphatase activity, potentially restoring or modulating signal transduction related to tumorigenesis, cellular differentiation, or other signaling pathways

03

Biological functions

Endosomal sorting (ESCRT-I complex interaction)Tumor suppressorRegulation of pre-mRNA splicingRegulation of small nuclear ribonucleoprotein assemblyCiliogenesisCardiac T-tubule formationNegative regulation of Ras-mediated mitogenic activity
04

Disease associations

Cancer (tumor suppressor function)Neurodevelopmental disordersStructural brain anomaliesNon-specific syndromic intellectual disabilityPotential role in heart failure (due to involvement in cardiac T-tubule maintenance)
05

Safety considerations

Targeting protein tyrosine phosphatases can lead to broad systemic effects due to their central role in cell signaling regulation, which may cause unintended effects on cell proliferation, apoptosis, and immune responsesSpecific safety concerns not characterized for PTPN23 specifically due to limited targeting in therapeutic development
06

Biomarkers

None established for patient selection or efficacy monitoring in clinical settingsmay serve as a biomarker for neurodevelopmental disorders and tumor suppression

Beyond the preview

Go deeper on Protein tyrosine phosphatase non-receptor type 23 (PTPN23).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein tyrosine phosphatase non-receptor type 23 (PTPN23).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call